Evaluating iCare COMPASS as a Visual Field Diagnostic Tool

this study seeks to compare the Humphrey Visual Field Analyzer and iCare COMPASS for both clinical accuracy and operational advantages.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

GLAUCOMA 1, OPEN ANGLE, D (Disorder) Eye Diseases Glaucoma Ocular Hypertension

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Eugene and Marilyn Glick Eye Institute

Indianapolis, Indiana, 46202, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All consenting patients who arrive for glaucoma management appointments for objective(s) 2.1.1, 2.2.2
Patient groups arriving for glaucoma management that will be targeted for enrollment include: glaucoma suspect patients, those with cataracts, optic atrophy, macular degeneration, macular pathology, and vascular diseases of the retina

Exclusion criteria

Those who are unwilling or unable to provide consent
Those for which English is not their first language

Treatment and study plan

Visual field testing

Diagnostic Test

This study will be a crossover study. Patients who express interest in taking part in the study will be evaluated using Humphrey SITA-faster, which is the current standard of care for visual perimetry, and the iCare COMPASS in the same visit. Participants will be assigned to one of two groups of alternating testing order with the Humphrey Visual Field Analyzer vs the iCare COMPASS and vice versa. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot results will be compared. For analysis, participants will be grouped according to the inclusion criteria.

Primary outcomes

Visual Fields will be assessed via the current standard of care Humphrey SITA-Faster when available. The mean deviation, pattern standard deviation, mean deviation cluster, and fixation plot obtained will be compared with the same measures on the iCare

Time frame: within 1-3 months post visit

Testing will be performed with either one or two encounters with the patient or as determined by the patients' clinician.

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Aug 14, 2026
Registry last updated: Aug 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed